EZR and ductal breast carcinoma in situ: This model is consistent with our observations that in relatively normal-appearing cells at the borders of human DCIS lesions, we see continued basolateral expression of HER2 while Ezrin and NHERF1 expression break the apical-lateral border and extend into the basolateral compartment to co-localize with HER2.